Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea

BACKGROUND: Real-world clinical data concerning regdanvimab, a monoclonal antibody treatment for patients with mild-to-moderate coronavirus disease 2019 (COVID-19), are urgently needed. Here, we describe our experience with regdanvimab. MATERIALS AND METHODS: This retrospective cohort study enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Sun In, Ryu, Byung-Han, Hong, Kyung-Wook, Bae, In-Gyu, Cho, Oh-Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987179/
https://www.ncbi.nlm.nih.gov/pubmed/35384423
http://dx.doi.org/10.3947/ic.2021.0143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987179/
https://www.ncbi.nlm.nih.gov/pubmed/35384423
http://dx.doi.org/10.3947/ic.2021.0143

Ejemplares similares